REMEGEN CO. LTD YC 1 (F:REG) — Market Cap & Net Worth
Market Cap & Net Worth: REMEGEN CO. LTD YC 1 (REG)
REMEGEN CO. LTD YC 1 (F:REG) has a market capitalization of $2.31 Billion (€1.98 Billion) as of May 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #5842 globally and #892 in its home market, demonstrating a 0.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying REMEGEN CO. LTD YC 1's stock price €9.48 by its total outstanding shares 208581239 (208.58 Million). Analyse REMEGEN CO. LTD YC 1 operating cash flow efficiency to see how efficiently the company converts income to cash.
REMEGEN CO. LTD YC 1 Market Cap History: 2021 to 2026
REMEGEN CO. LTD YC 1's market capitalization history from 2021 to 2026. Data shows change from $1.96 Billion to $2.31 Billion (-1.55% CAGR).
REMEGEN CO. LTD YC 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how REMEGEN CO. LTD YC 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.60x
REMEGEN CO. LTD YC 1's market cap is 0.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.75x
REMEGEN CO. LTD YC 1's market cap is 2.75 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.96 Billion | $1.42 Billion | $276.26 Million | 1.38x | 7.11x |
| 2022 | $1.71 Billion | $767.77 Million | -$998.83 Million | 2.22x | N/A |
| 2023 | $1.05 Billion | $1.08 Billion | -$1.51 Billion | 0.97x | N/A |
| 2024 | $421.87 Million | $1.71 Billion | -$1.47 Billion | 0.25x | N/A |
| 2025 | $1.95 Billion | $3.24 Billion | $709.65 Million | 0.60x | 2.75x |
Competitor Companies of REG by Market Capitalization
Companies near REMEGEN CO. LTD YC 1 in the global market cap rankings as of May 22, 2026.
Key companies related to REMEGEN CO. LTD YC 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
REMEGEN CO. LTD YC 1 Historical Marketcap From 2021 to 2026
Between 2021 and today, REMEGEN CO. LTD YC 1's market cap moved from $1.96 Billion to $ 2.31 Billion, with a yearly change of -1.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.31 Billion | +18.52% |
| 2025 | €1.95 Billion | +362.43% |
| 2024 | €421.87 Million | -59.77% |
| 2023 | €1.05 Billion | -38.57% |
| 2022 | €1.71 Billion | -13.04% |
| 2021 | €1.96 Billion | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of REMEGEN CO. LTD YC 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.31 Billion USD |
| MoneyControl | $2.31 Billion USD |
| MarketWatch | $2.31 Billion USD |
| marketcap.company | $2.31 Billion USD |
| Reuters | $2.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About REMEGEN CO. LTD YC 1
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Ve… Read more